Bank of New York Mellon
RVPH

Bank of New York Mellon’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Bank of New York Mellon’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-752
Closed -$63K – 4450
2023
Q1 		$63K Buy
752
+25
+3% +$2.18K ﹤0.01% 4151
2022
Q4 		$61.8K Buy
+727
New +$55.4K ﹤0.01% 4203

Other funds holding RVPH

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Bank of New York Mellon's RVPH Position: Q2 2023 in Review

Bank of New York Mellon sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q2 2023, closing a stake of 752 shares — an estimated $63K sold.

Bank of New York Mellon first reported a position in RVPH in Q4 2022 and held it in 2 quarters. The position peaked at $63K in Q1 2023. 23 funds tracked by Wall St. Rank hold RVPH as of Q2 2023.

  • Bank of New York Mellon reported no remaining REVIVA PHARMA HLDGS INC position as of Q2 2023 after selling out during the quarter.
  • Bank of New York Mellon sold 752 REVIVA PHARMA HLDGS INC shares in Q2 2023, an estimated $63K.
  • Bank of New York Mellon first reported a position in REVIVA PHARMA HLDGS INC in Q4 2022 and held it in 2 quarters.
  • Bank of New York Mellon's REVIVA PHARMA HLDGS INC position peaked at $63K in Q1 2023.
  • 23 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q2 2023.

Based on Bank of New York Mellon's 13F filing for Q2 2023, filed 3 Aug 2023.